AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Lexicon Pharmaceuticals, Inc.
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG001SDWCZ8
1.42▼ 0.07 (-4.70%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close
1.49
Day's Range
1.37 – 1.50
52-Week Range
1.10 – 2.68
Volume
2.7M
Avg Volume
2.7M
Share Statistics
Shares Outstanding
Employees
81
Exchange
XNAS
Listed
2000-04-07
Share count as of August 3, 2026

Lexicon Pharmaceuticals, Inc. (LXRX) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Lexicon Pharmaceuticals, Inc. (LXRX)
What is Lexicon Pharmaceuticals, Inc.'s Market Cap?
Lexicon Pharmaceuticals, Inc.'s Market Cap is $631.8M, based on as-reported figures from SEC (XBRL) filings.
What is Lexicon Pharmaceuticals, Inc.'s Enterprise Value?
Lexicon Pharmaceuticals, Inc.'s Enterprise Value is $492.7M, based on as-reported figures from SEC (XBRL) filings.
What is Lexicon Pharmaceuticals, Inc.'s Price / Sales?
Lexicon Pharmaceuticals, Inc.'s Price / Sales is 15.2×, based on as-reported figures from SEC (XBRL) filings.
What is Lexicon Pharmaceuticals, Inc.'s EV / Revenue?
Lexicon Pharmaceuticals, Inc.'s EV / Revenue is 11.9×, based on as-reported figures from SEC (XBRL) filings.
What is Lexicon Pharmaceuticals, Inc.'s EV / EBITDA?
Lexicon Pharmaceuticals, Inc.'s EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Lexicon Pharmaceuticals, Inc.'s Revenue (TTM)?
Lexicon Pharmaceuticals, Inc.'s Revenue (TTM) is $41.5M, based on as-reported figures from SEC (XBRL) filings.
What is Lexicon Pharmaceuticals, Inc.'s Net Income (TTM)?
Lexicon Pharmaceuticals, Inc.'s Net Income (TTM) is -$61.1M, based on as-reported figures from SEC (XBRL) filings.
What is Lexicon Pharmaceuticals, Inc.'s EBITDA?
Lexicon Pharmaceuticals, Inc.'s EBITDA is -$54.0M, based on as-reported figures from SEC (XBRL) filings.
What is Lexicon Pharmaceuticals, Inc.'s Diluted EPS (TTM)?
Lexicon Pharmaceuticals, Inc.'s Diluted EPS (TTM) is -0.14, based on as-reported figures from SEC (XBRL) filings.
What is Lexicon Pharmaceuticals, Inc.'s EBITDA Margin?
Lexicon Pharmaceuticals, Inc.'s EBITDA Margin is -130.3%, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · LXRXAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenues:
Net product and licensing revenue———
Royalties and other revenue
Total revenues
YoY growth-97.6%+1572.1%-79.3%+710.4%
Operating expenses:
Cost of sales
Research and development
Selling, general and administrative, including stock-based compensation of $1,952, $1,575, $3,661, and $3,044 respectively
Total operating expenses
% of revenue3935.3%104.7%369.1%185.9%
(Loss) income from operations
% of revenue-3835.3%-4.7%-269.1%-85.9%
Interest and other expense
Interest and other income
Gain (Loss) on Extinguishment of Debt———
Net loss
% of revenue-4591.8%-4.9%-282.7%-90.0%
Net loss per common share, basic (usd per share)
Net loss per common share, diluted (usd per share)